Celltrion says Korea regulator clears CT-P13 SC Phase 3 rheumatoid arthritis trial plan

Bitget2026/10/14 09:24

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

South Korea’s MFDS cleared Celltrion’s Phase 3 trial plan for CT-P13 SC (Zymfentra) in rheumatoid arthritis.
Global, randomized, placebo-controlled study targets 296 patients with 52 weeks of treatment.
Primary endpoint targets ACR50 response at week 12.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celltrion Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261014800646), on October 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Celltrion says Korea regulator clears CT-P13 SC Phase 3 rheumatoid arthritis trial plan

You may also like

Crypto prices